TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30394805

Group type: EXPERIMENTAL
Intervention: Daflon® for 1 month
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Daflon® for 3 months
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 450
Study: 29493163

Group type: EXPERIMENTAL
Intervention: ACPV decoction (treatment group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deanxit (control group)
Number of subjects: 60
Study: 25409167

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac (90 mg)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 23328126

Group type: EXPERIMENTAL
Intervention: Omega-3-Acid Ethyl Esters (4 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21806837

Group type: EXPERIMENTAL
Intervention: Classic Yin and Yang Tonic Granule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19836709

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft combined with Fisiograft
Number of subjects: 16

Group type: COMPARATOR
Intervention: Autogenous bone graft alone
Number of subjects: 16
Study: 17086021

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/d
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/d
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d + Quinapril 20 mg/d
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy normotensive subjects (normal)
Number of subjects: 63
Study: 15577824

Group type: EXPERIMENTAL
Intervention: Sensitization to food or aeroallergens
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Aeroallergen sensitization
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Blood eosinophil level of 4% or greater
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Total serum IgE level greater than 100 IU/mL
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Eosinophilia and total serum IgE level correlation with aeroallergen sensitization
Number of subjects: 285
Study: 12033350

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy or ICD
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Inducible patients with ICD
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 109
Study: 9661649

Group type: EXPERIMENTAL
Intervention: Cortisol-producing adenoma
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Androgen-secreting adrenocortical carcinoma
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aldosterone-producing adenoma
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nonfunctional adenomas
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aldosterone-producing adenomas
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cortisol-producing adenomas
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal adrenals
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Adrenocortical tumors
Number of subjects: 19
Study: 7662596

Group type: EXPERIMENTAL
Intervention: Celiprolol treatment
Number of subjects: 25
Study: 2694006

Group type: EXPERIMENTAL
Intervention: Calciheparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Defibrotide
Number of subjects: 20
Study: 361799

Group type: EXPERIMENTAL
Intervention: Vincristine associated with cyclophosphamide and 5-fluoro-uracil
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Doxorubicine
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 603
Study: 31002317

Group type: EXPERIMENTAL
Intervention: Minimally interrupted dabigatran therapy
Number of subjects: 442

Group type: COMPARATOR
Intervention: Uninterrupted warfarin therapy
Number of subjects: 442
Study: 28599894

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study: 26635204

Group type: EXPERIMENTAL
Intervention: AF-inducing specially processed cereals (SPC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control cereal)
Number of subjects: 32
Study: 24048776

Group type: EXPERIMENTAL
Intervention: Symphytum herb extract cream
Number of subjects: 161
Study: 22691828

Group type: EXPERIMENTAL
Intervention: Tachosil® (hemostatic-sealant drug) used as a reinforcement of the suture line in sleeve gastrectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no Tachosil®)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tachosil®
Number of subjects: 30
Study: 19874077

Group type: EXPERIMENTAL
Intervention: Modified Astrand bicycle test
Number of subjects: 64

Group type: COMPARATOR
Intervention: Astrand bicycle test
Number of subjects: 64
Study: 17335391

Group type: EXPERIMENTAL
Intervention: Frontal eye field and visual cortex activity during successful goal-directed saccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural activity following saccadic movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Error-related activity in the frontal eye fields
Number of subjects: 0
Study: 15371022

Group type: EXPERIMENTAL
Intervention: African American client portrayal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: European American client portrayal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asian American client portrayal
Number of subjects: 0
Study: 11479066

Group type: EXPERIMENTAL
Intervention: 15-month intervention program
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Follow-up after 15 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Follow-up study
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Referral to other mental health agencies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Continuity of outpatient care
Number of subjects: 76
Study: 9153724

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 260

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 260
Study: 7954550

Group type: EXPERIMENTAL
Intervention: Xipamide, 20 mg/day
Number of subjects: 139

Group type: COMPARATOR
Intervention: Spironolactone, 200 mg/day combined with furosemide, 40 mg on alternate days
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Torasemide, 10-40 mg/day combined with spironolactone, 50-400 mg/day
Number of subjects: 139
Study: 3661610

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g suspension four times daily for eight weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cimetidine 400 mg four times daily for eight weeks
Number of subjects: 42
Study: 31912660

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 96

Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 96
Study: 29452589

Group type: EXPERIMENTAL
Intervention: Web-based intervention (G1)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Web + e-mail intervention (G2)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Web + SMS intervention (G3)
Number of subjects: 608
Study: 27624835

Group type: EXPERIMENTAL
Intervention: Financial incentive payments with audit plus feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Financial incentive payments without audit plus feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audit plus feedback without financial incentive payments
Number of subjects: 0

Group type: COMPARATOR
Intervention: No financial incentive payments and no audit plus feedback
Number of subjects: 0
Study: 25277496

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 0
Study: 22429969

Group type: EXPERIMENTAL
Intervention: Adrenaline (epinephrine)
Number of subjects: 174

Group type: COMPARATOR
Intervention: No adrenaline
Number of subjects: 174
Study: 20831680

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 473

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 473
Study: 18224352

Group type: EXPERIMENTAL
Intervention: Transmuscular approach (TM) with expandable tubular retractor
Number of subjects: 125

Group type: COMPARATOR
Intervention: Subperiosteal approach (SP) with speculum-counter-retractor
Number of subjects: 125
Study: 16325039

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 12570120

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (200 microg twice daily)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 730
Study: 10671811

Group type: COMPARATOR
Intervention: Normal pregnancies
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Missed abortions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Normal pregnancies and missed abortions
Number of subjects: 50
Study: 8895621

Group type: EXPERIMENTAL
Intervention: Surgical closure in flexion (90 to 110 degrees)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Surgical closure in extension
Number of subjects: 108
Study: 1382539

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (63 pmol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anaesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsaicin pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetirizine (10 mg orally, 4 h before injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (0.3-10 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbachol (1-30 microM)
Number of subjects: 0
Study: 3988974

Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg/day for 6 weeks
Number of subjects: 83
Study: 29746294

Group type: EXPERIMENTAL
Intervention: 3-day per week Atripla regimen (3W)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Once daily Atripla regimen (OD)
Number of subjects: 61
Study: 27485727

Group type: EXPERIMENTAL
Intervention: Modified advance notification letter
Number of subjects: 9216

Group type: COMPARATOR
Intervention: Standard invitation material (control group)
Number of subjects: 9216

Group type: EXPERIMENTAL
Intervention: Modified invitation letter
Number of subjects: 9216
Study: 26352144

Group type: EXPERIMENTAL
Intervention: U‐HRCT scanner (0.25 mm x 4 rows, 120 mAs)
Number of subjects: 37

Group type: COMPARATOR
Intervention: C‐HRCT scanner (0.5 mm x 16 or 0.5 mm x 64 rows, 150 mAs)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: U‐HRCT scanner
Number of subjects: 37

Group type: COMPARATOR
Intervention: C‐HRCT scanner
Number of subjects: 37
Study: 23924587

Group type: EXPERIMENTAL
Intervention: Adefovir (ADV) therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21668806

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18195173

Group type: EXPERIMENTAL
Intervention: Clopidogrel 0.20 mg/kg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 16774980

Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0-3.0)
Number of subjects: 2257

Group type: COMPARATOR
Intervention: Ximelagatran (36 mg twice daily)
Number of subjects: 2257

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2257
Study: 12509377

Group type: EXPERIMENTAL
Intervention: Interventions used to promote patient recruitment
Number of subjects: 6070

Group type: EXPERIMENTAL
Intervention: Organizational characteristics
Number of subjects: 6070

Group type: EXPERIMENTAL
Intervention: Presence of 'favourable' organizational characteristics
Number of subjects: 6070
Study: 11092064

Group type: EXPERIMENTAL
Intervention: Nicotine 2‐mg sublingual tablet
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 8973871

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patients with RA
Number of subjects: 101
Study: 1534211

Group type: EXPERIMENTAL
Intervention: Teicoplanin 3 mg/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Teicoplanin 12 mg/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Teicoplanin 30 mg/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined results of all doses (3, 12, 30 mg/kg)
Number of subjects: 23
Study: 6330886

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both ranitidine and famotidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 28-day famotidine treatment
Number of subjects: 0
Study: 28810429

Group type: EXPERIMENTAL
Intervention: Pain sensitivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared human alarm system of unfairness and pain sensitivity
Number of subjects: 0
Study: 29800211

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly dosing (225 mg at baseline, week 4, and week 8)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Fremanezumab single higher dose (675 mg at baseline; placebo at weeks 4 and 8)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo (at baseline, week 4, and week 8)
Number of subjects: 875
Study: 26294680

Group type: EXPERIMENTAL
Intervention: Pilates-based program once a week for 6 weeks
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Pilates-based program twice a week for 6 weeks
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Pilates-based program three times a week for 6 weeks
Number of subjects: 296

Group type: COMPARATOR
Intervention: Educational booklet only (control group)
Number of subjects: 296
Study: 24478399

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin infusion during clamp
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intralipid/heparin mixture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22441580

Group type: EXPERIMENTAL
Intervention: Low-frequency electrotherapy (LFE) for normal compliance (LFE-NC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-frequency electrotherapy (LFE) for low compliance (LFE-LC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conservative treatment for normal compliance (CON-NC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conservative treatment for low compliance (CON-LC)
Number of subjects: 102
Study: 21067061

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 28
Study: 17362728

Group type: EXPERIMENTAL
Intervention: Belzer solution
Number of subjects: 51

Group type: COMPARATOR
Intervention: Custodiol solution
Number of subjects: 51
Study: 16248984

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (60mg/day for 4 weeks)
Number of subjects: 21
Study: 12271807

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus routine care
Number of subjects: 315

Group type: COMPARATOR
Intervention: Supportive counselling plus routine care
Number of subjects: 315

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 315
Study: 10414537

Group type: EXPERIMENTAL
Intervention: Mini-laparoscopic cholecystectomy (mini-LC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (C-LC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (mini-LC and C-LC)
Number of subjects: 200
Study: 8789468

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (COMB-HC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard circuits (COMB-C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (CABG-HC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard circuits (CABG-C)
Number of subjects: 20
Study: 1498296

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.15 mg/kg bolus followed by 2 micrograms/kg/min)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 29
Study: 6366822

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30667502

Group type: EXPERIMENTAL
Intervention: Low free sugar diet (restricted to less than 3% of daily calories for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual diet (participants consumed their regular diet)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low free sugar diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 40
Study: 29127945

Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 95

Group type: COMPARATOR
Intervention: CBM-I
Number of subjects: 95

Group type: COMPARATOR
Intervention: Combined ABMT + CBM-I
Number of subjects: 95

Group type: COMPARATOR
Intervention: Combined control
Number of subjects: 95
Study: 27640607

Group type: EXPERIMENTAL
Intervention: naproxen plus oxycodone/acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: naproxen plus cyclobenzaprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: naproxen plus placebo
Number of subjects: 0
Study: 24528604

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) for elderly patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62
Study: 22920800

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin + recombinant human hyaluronidase (rHuPH20)
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of rapid-acting insulin + rHuPH20
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of rapid-acting insulin + rHuPH20
Number of subjects: 60000
Study: 21056840

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture and behavior therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham electro-acupuncture and behavior therapy
Number of subjects: 180
Study: 17380679

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 360
Study: 15797276

Group type: EXPERIMENTAL
Intervention: Clinical Decision Rule (CDR) for identifying pulmonary embolism (PE) as a cause of cardiac arrest
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pre-arrest clinical triad of respiratory distress, altered mental status, and shock
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Witnessed arrests by EMS or ED physicians
Number of subjects: 44
Study: 12015525

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 130
Study: 10535857

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg + Vitamin E 100 mg twice daily
Number of subjects: 145
Study: 8584522

Group type: EXPERIMENTAL
Intervention: 0.2 mg Fenoterol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2 mg Salbutamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.05 mg Salmeterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rescue medication (Salbutamol MDI)
Number of subjects: 15
Study: 2338888

Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg/h for 4 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 6116950

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 30728064

Group type: EXPERIMENTAL
Intervention: Peer-led web-based intervention to promote safe usage of dating applications
Number of subjects: 338

Group type: COMPARATOR
Intervention: Web-based resource on health and exercise (Control)
Number of subjects: 338
Study: 27770498

Group type: EXPERIMENTAL
Intervention: Single treadmill running session
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long-term individual shear rate therapy (ISRT)
Number of subjects: 40
Study: 26578736

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 400 mg/day plus metformin 750-2250 mg/day for 24-36 weeks
Number of subjects: 36
Study: 24948402

Group type: EXPERIMENTAL
Intervention: memantine (maximal dose 20 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dextromethorphan (maximal dose 90 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dextromethorphan
Number of subjects: 60
Study: 22271868

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pharmacological inhibition of NO and prostanoid systems
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acetylcholine-induced response
Number of subjects: 10
Study: 19934286

Group type: EXPERIMENTAL
Intervention: CH4987655 (0.5, 1, 2, 3, and 4 mg)
Number of subjects: 40
Study: 18062141

Group type: EXPERIMENTAL
Intervention: Gardasil vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15279530

Group type: EXPERIMENTAL
Intervention: Universal classroom-based intervention
Number of subjects: 0
Study: 11437394

Group type: EXPERIMENTAL
Intervention: High-dose IM Medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy during 6 months
Number of subjects: 516

Group type: COMPARATOR
Intervention: No hormonotherapy
Number of subjects: 516
Study: 9544333

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride injection with heparin sodium 10 units/mL
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection without heparin sodium
Number of subjects: 58
Study: 7916540

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment of Negative Symptoms
Number of subjects: 207